Antibodies for
Immunohistochemistry
Cytokeratin 5 & 6 (D5 & 16B4)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45300 IMPATH Cytokeratin 5&6 RTU M (D5 & 16B4) 50 Tests
44271 Cytokeratin 5&6 RTU M (D5/16B4)
7 ml Ready To Use
44563 Cytokeratin 5&6 0,1 M (D5/16B4)
100 µl liquid Concentrated
44564 Cytokeratin 5&6 1 M (D5/16B4)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Mesothelioma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
& IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Anti-CK 5 & 6 positivity is seen in nearly 100% of malignant mesotheliomas and in nearly 0% of lung adenocarcinomas. Anti-CK 5 & 6 positivity
can be seen in undifferentiated large cell carcinoma as well as squamous carcinoma, and has been useful in recognizing spindle cell squamous
cell carcinoma of the skin. Less than 10% of carcinomas of the breast, colon, and prostate stain positively for this marker. Anti-CK 5 & 6 has also
been used successfully as a myoepithelial cell marker in the prostate and breast to determine malignancy. Anti-CK 5 & 6 is a useful marker to
distinguish lung squamous cell carcinoma from lung adenocarcinoma and large cell carcinoma within a panel including antibodies against TTF-1,
Napsin A, p63, SOX2, desmocollin3, and desmoglein3.
Pleura: Adenocarcinoma vs. Mesothelioma
CK 5&6 Calretinin D2-40 HBME-1 Caldesmon CEA TAG-72 Ep-CAM E-cadherin TTF-1
Adenocarcinoma
-
-
-
-
-
+
+
+
+
+
Mesothelioma
+
+
+
+
+
-
-
-
-
-
Carcinomas
CK 5&6
CK
Cocktail
CK 7
CK 20
p63
ER/PR CD10
CEA CK, HMW CK, LMW
Salivary Gland Carcinoma
+
+
+
-
+
-
+
+
+
Ovarian Carcinoma
+
+
+
-
-
-
-
-
+
+
Sweat Gland Carcinoma
+
+
+
-
+
+
+
+
+
Squamous Cell Carcinoma
+
+
-
-
+
-
-
-
Transitional Cell Carcinoma
+
+
+
+
+
-
+
-
+
+
Colon vs. Ovarian Carcinoma
CK 5&6 CK 7
CK 20
CEA CDX-2
Villin CA19-9 Ep-CAM WT1 CA-125
Ovarian Carcinoma, Serous
-
+
-
+
-
+
+
+
+
+
Ovarian Carcinoma,
Mucinous
+
-
-
+
+
+
+
-
-
Ovarian Endometrioid Ca
-
+
-
-
-
+/-
+
+
+
Colon Carcinoma
-
-
+
+
+
+
+
+
-
-
Reference
1. Ordonez NG. Am J Surg Pathol. 1998; 22(10):1215-1221.
2. Ordonez NG. Am J Surg Pathol. 1998; 22(10):1203-1214.
3. Cury PM, Butcher DW, et al. Mod Pathol. 2000; 13(2):107-12.
98
